Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 35% ± 14% | |
glutamatergic neuron | 12 studies | 61% ± 27% | |
microglial cell | 11 studies | 32% ± 12% | |
GABAergic neuron | 10 studies | 46% ± 24% | |
fibroblast | 7 studies | 27% ± 9% | |
smooth muscle cell | 6 studies | 26% ± 4% | |
adipocyte | 6 studies | 23% ± 4% | |
endothelial cell of lymphatic vessel | 5 studies | 32% ± 7% | |
oligodendrocyte precursor cell | 5 studies | 22% ± 5% | |
type I pneumocyte | 5 studies | 27% ± 4% | |
neuron | 4 studies | 27% ± 14% | |
pericyte | 4 studies | 30% ± 2% | |
interneuron | 4 studies | 60% ± 25% | |
hepatic stellate cell | 3 studies | 43% ± 7% | |
GABAergic interneuron | 3 studies | 56% ± 2% | |
macrophage | 3 studies | 29% ± 11% | |
club cell | 3 studies | 25% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 13 studies | 42% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 528.72 | 456 / 459 | 94% | 4.99 | 1049 / 1118 |
lung | 96% | 234.45 | 556 / 578 | 85% | 3.37 | 986 / 1155 |
skin | 90% | 264.61 | 1624 / 1809 | 92% | 9.33 | 433 / 472 |
thymus | 98% | 248.37 | 640 / 653 | 71% | 1.60 | 429 / 605 |
uterus | 87% | 217.99 | 148 / 170 | 58% | 2.87 | 266 / 459 |
bladder | 81% | 317.48 | 17 / 21 | 61% | 1.96 | 308 / 504 |
brain | 61% | 165.16 | 1604 / 2642 | 75% | 2.58 | 530 / 705 |
esophagus | 53% | 96.69 | 769 / 1445 | 78% | 2.63 | 142 / 183 |
intestine | 49% | 89.89 | 477 / 966 | 61% | 1.76 | 324 / 527 |
liver | 69% | 154.55 | 155 / 226 | 42% | 1.01 | 169 / 406 |
stomach | 28% | 42.64 | 100 / 359 | 74% | 2.49 | 213 / 286 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.48 | 1 / 1 |
blood vessel | 100% | 1514.36 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 796.22 | 1203 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 15.98 | 78 / 80 |
pancreas | 4% | 5.74 | 13 / 328 | 92% | 4.34 | 163 / 178 |
kidney | 18% | 23.02 | 16 / 89 | 65% | 3.09 | 588 / 901 |
prostate | 49% | 90.88 | 120 / 245 | 29% | 0.58 | 145 / 502 |
ovary | 23% | 45.31 | 41 / 180 | 51% | 1.43 | 219 / 430 |
tonsil | 0% | 0 | 0 / 0 | 67% | 2.44 | 30 / 45 |
heart | 56% | 106.42 | 485 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 6% | 8.70 | 16 / 258 | 47% | 1.48 | 108 / 230 |
muscle | 52% | 80.36 | 419 / 803 | 0% | 0 | 0 / 0 |
spleen | 31% | 40.11 | 74 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.20 | 4 / 29 |
peripheral blood | 0% | 0.09 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030206 | Biological process | chondroitin sulfate biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0032580 | Cellular component | Golgi cisterna membrane |
GO_0050510 | Molecular function | N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0047238 | Molecular function | glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity |
Gene name | CHSY3 |
Protein name | Chondroitin sulfate synthase 3 (EC 2.4.1.175) (EC 2.4.1.226) (Carbohydrate synthase 2) (Chondroitin glucuronyltransferase 3) (Chondroitin synthase 2) (ChSy-2) (Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II) (N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 3) (N-acetylgalactosaminyltransferase 3) |
Synonyms | CHSY2 CSS3 |
Description | FUNCTION: Has both beta-1,3-glucuronic acid and beta-1,4-N-acetylgalactosamine transferase activity. Transfers glucuronic acid (GlcUA) from UDP-GlcUA and N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of the elongating chondroitin polymer. Specific activity is much reduced compared to CHSY1. . |
Accessions | Q70JA7 ENST00000305031.5 |